Instil Bio (TIL) Non Operating Income (2020 - 2025)
Instil Bio (TIL) posted Non Operating Income of -$55000.0 for Q4 2025, up 53.39% on a QoQ basis from -$118000.0 in Q3 2025, and up 95.41% year-over-year from -$28146.1 in Q4 2024.
Powered by 
Analysis
Instil Bio (TIL) Non Operating Income (2020 - 2025) Analysis & Trends
Instil Bio has reported Non Operating Income for 6 years, with the latest figure at -$55000.0 in Q4 2025.
- On a quarterly basis, Non Operating Income rose 95.41% year-over-year to -$55000.0 in Q4 2025; TTM through Dec 2025 was $212000.0, a 107.42% increase from a year earlier, with the FY2025 full-year figure at $212000.0, up 107.42% from the prior year.
- Non Operating Income was -$55000.0 for Q4 2025 at Instil Bio, up from -$118000.0 in the prior quarter.
- The five-year high for Non Operating Income was $1.3 million in Q4 2022, with the low at -$1.2 million in Q4 2024.
- Average Non Operating Income over 5 years is -$252600.0, with a median of -$267500.0 recorded in 2022.
- The sharpest annual moves came in 2022 and 2024: Non Operating Income jumped 326.7% in 2022, then sank 898.33% in 2024.
- Over 5 years, Non Operating Income stood at -$573000.0 in 2021, then surged by 326.7% to $1.3 million in 2022, then sank by 109.24% to -$120000.0 in 2023, then tumbled by 898.33% to -$1.2 million in 2024, then jumped by 95.41% to -$55000.0 in 2025.
- The last three Non Operating Income figures came in at -$55000.0 (Q4 2025), -$118000.0 (Q3 2025), and $342000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -73.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 387.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 234.30 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Instil Bio | 50.19 Mn | 50.19 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -55,000.00 |
| Sep 30, 2025 | -118,000.00 |
| Jun 30, 2025 | 342,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Dec 31, 2024 | -1.20 Mn |
| Sep 30, 2024 | -530,000.00 |
| Jun 30, 2024 | -702,000.00 |
| Mar 31, 2024 | -428,000.00 |
| Dec 31, 2023 | -120,000.00 |
| Sep 30, 2023 | -1.03 Mn |
| Jun 30, 2023 | 628,000.00 |
| Mar 31, 2023 | -57,000.00 |
| Dec 31, 2022 | 1.30 Mn |
| Sep 30, 2022 | -415,000.00 |
| Jun 30, 2022 | -1.03 Mn |
| Mar 31, 2022 | -416,000.00 |
| Dec 31, 2021 | -573,000.00 |
| Sep 30, 2021 | -661,000.00 |
| Jun 30, 2021 | -104,000.00 |
| Mar 31, 2021 | 71,000.00 |